219 related articles for article (PubMed ID: 28390927)
41. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
42. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
[TBL] [Abstract][Full Text] [Related]
43. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
44. The Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: An Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique.
Khademi F; Mohammadi P; Mostafaei A
Iran J Allergy Asthma Immunol; 2021 Apr; 20(2):205-220. PubMed ID: 33904679
[TBL] [Abstract][Full Text] [Related]
45. Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy.
Zhou K; Hong H; Lin H; Gong L; Li D; Shi J; Zhou Z; Xu F; Wu Z
J Med Chem; 2022 Jan; 65(1):323-332. PubMed ID: 34962121
[TBL] [Abstract][Full Text] [Related]
46. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
47. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
48. The transgenic chicken derived anti-CD20 monoclonal antibodies exhibits greater anti-cancer therapeutic potential with enhanced Fc effector functions.
Kim YM; Park JS; Kim SK; Jung KM; Hwang YS; Han M; Lee HJ; Seo HW; Suh JY; Han BK; Han JY
Biomaterials; 2018 Jun; 167():58-68. PubMed ID: 29554481
[TBL] [Abstract][Full Text] [Related]
49. Complement activation determines the therapeutic activity of rituximab in vivo.
Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
[TBL] [Abstract][Full Text] [Related]
50. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
51. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
52. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
[TBL] [Abstract][Full Text] [Related]
53. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.
Tobin E; Denardo G; Zhang N; Epstein AL; Liu C; Denardo S
Leuk Lymphoma; 2007 May; 48(5):944-56. PubMed ID: 17487739
[TBL] [Abstract][Full Text] [Related]
54. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
[TBL] [Abstract][Full Text] [Related]
55. Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.
Wu X; Ragupathi G; Panageas K; Hong F; Livingston PO
Clin Cancer Res; 2013 Sep; 19(17):4728-39. PubMed ID: 23833306
[TBL] [Abstract][Full Text] [Related]
56. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
[TBL] [Abstract][Full Text] [Related]
57. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
58. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
59. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; de Jong RN; Beurskens FJ; Schuurman J; Parren PW; Taylor RP
Mol Immunol; 2016 Feb; 70():13-23. PubMed ID: 26690706
[TBL] [Abstract][Full Text] [Related]
60. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Dahle J; Repetto-Llamazares AH; Mollatt CS; Melhus KB; Bruland OS; Kolstad A; Larsen RH
Anticancer Res; 2013 Jan; 33(1):85-95. PubMed ID: 23267131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
